This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Date and time:

30.06.24 at 12:45-13:45 EEST



Welcome and introduction

Delivering on the promise of blood-based biomarkers for the diagnosis of early Alzheimer’s disease

Looking beyond amyloid and tau for treating Alzheimer’s disease: Emerging therapies aimed at novel targets

European perspectives on the future of Alzheimer’s disease care: Impact of advancements in diagnosis and treatment

Innovation in Alzheimer’s disease: optimising clinical practice with a focus on effectiveness and ease of disease management

Summary and close


Michael Heneka

University of Luxembourg, Esch-sur-Alzette, Luxembourg

Dr Heneka earned his medical degree at the Institute of Pharmacology, for which he received the 1998 Attempto Award of the University of Tübingen, Germany. He started his clinical residency in neurology at the Department of Neurology of the University of Tübingen in 1996 and joined the Department of Neurology at the University of Bonn in 1999. After his clinical board examination (2002) and habilitation (2003), he took the chair as Professor for Molecular Neurology at the University of Münster in 2004. In 2008, he was appointed Professor for Clinical Neurosciences at the University of Bonn, heading the German Research Foundation (DFG) Clinical Research Unit 177.


Dr Heneka has more than 25 years of experience studying neurodegenerative disease at the experimental, preclinical and clinical level. While the main focus of his work is related to dementia and Alzheimer’s disease, he has also been working on amyotrophic lateral sclerosis and Parkinson’s disease. At the clinical level, he has established a neurodegenerative outpatient unit at the University of Münster and thereafter at the University of Bonn from 2008 to 2016.


He has served as a board member on several networks, task forces and steering committees, and a panel member for German national dementia guidelines. Next to his role as Associate Editor of Alzheimer’s Research & Therapy, and editorial board member of various neuroscience journals, Dr Heneka serves as a scientific advisory board member of the Paris Brain Institute in France and the Dementia Research Institute in the UK. He is the organiser of the biannual meeting ‘Venusberg Meeting on Neuroinflammation’ since 2009, as well as co-organiser of various international meetings and symposia.


Dr Heneka has published more than 300 peer-reviewed manuscripts in internationally recognised journals including Nature, Cell, Nature Immunology and Lancet Neurology, and has been identified as a Clarivate Highly Cited Researcher since 2018.

Read full bio